Compare ALV & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALV | TECH |
|---|---|---|
| Founded | 1953 | 1976 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.5B |
| IPO Year | 1997 | 1989 |
| Metric | ALV | TECH |
|---|---|---|
| Price | $120.85 | $58.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $133.45 | $71.23 |
| AVG Volume (30 Days) | 585.2K | ★ 1.9M |
| Earning Date | 01-30-2026 | 02-04-2026 |
| Dividend Yield | ★ 2.81% | 0.55% |
| EPS Growth | ★ 25.57 | N/A |
| EPS | ★ 9.69 | 0.49 |
| Revenue | ★ $10,614,000,000.00 | $1,216,732,000.00 |
| Revenue This Year | $4.73 | $2.33 |
| Revenue Next Year | $4.40 | $7.05 |
| P/E Ratio | ★ $12.49 | $119.71 |
| Revenue Growth | 0.85 | ★ 3.85 |
| 52 Week Low | $75.49 | $46.01 |
| 52 Week High | $129.54 | $79.28 |
| Indicator | ALV | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 42.98 |
| Support Level | $118.76 | $56.84 |
| Resistance Level | $122.75 | $61.20 |
| Average True Range (ATR) | 2.30 | 2.01 |
| MACD | 0.30 | -0.53 |
| Stochastic Oscillator | 70.35 | 18.93 |
Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.